Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Neuroprotective Effects of GLP1R Agonists Semaglutide and Terzepatide via Microglial Modulation in Neonatal Hypoxic-Ischemic Brain Injury

EF 2024-25

Résumé
Neonatal hypoxic-ischemic brain injury (HIBI) and subsequent encephalopathy (HIE) are debilitating conditions resulting from insufficient cerebral perfusion and oxygenation in the brain. These events often lead to long-term cognitive and motor deficits, causing disorders such as cerebral palsy, epilepsy, and, in severe cases, death. Current therapeutic standards for neonates include hypothermia, which offers partial efficacy. Currently, there are no pharmacological interventions available to alleviate HIE, promoting the need for further research. Glucagon-like-peptide-1 receptor (GLP-1R) agonists have become a potential therapeutic target due to their anti-inflammatory and neuroprotective role in various insults to the central nervous system. However, the role of GLP-1R in M1/M2 microglial polarization and regulation in the context of neonatal HIBI is still unclear.Therefore, it is critical to study the mechanism and modulation of microglia through GLP-1R in HIBI. This study aims to investigate the neuroprotective effects of GLP-1R agonists Terzepatide and Semaglutide in neonatal HIBI. We hypothesize that these agonists will promote neuroprotection by shifting microglial polarization towards the M2 anti-inflammatory phenotype, alleviating injury. We will utilize a HIBI model induced in CD1 transgenic and wild-type mice, followed by drug intervention, and measure short- and long-term neurobehavioral function. We will also assess brain morphology through staining and assess M1/M2 microglial polarization through inflammatory markers via western blots, immunohistochemistry, and primers in qPCR. This study will help elucidate the neuroprotective mechanism of GLP-1R agonists, offering new therapeutic interventions for clinical practice.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
530342
Name
Ali Muhammad
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Neuroprotective Effects of GLP1R Agonists Semaglutide and Terzepatide via Microglial Modulation in Neonatal Hypoxic-Ischemic Brain Injury
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Glp-1r; Glp-1r Agonist; Hypoxic Brain Injury; Ischemic Stroke; Microglia; Neonatal Stroke; Neuroinflammation; Neuroprotection; Neurotrophic; Stroke
Abstract
Neonatal hypoxic-ischemic brain injury (HIBI) and subsequent encephalopathy (HIE) are debilitating conditions resulting from insufficient cerebral perfusion and oxygenation in the brain. These events often lead to long-term cognitive and motor deficits, causing disorders such as cerebral palsy, epilepsy, and, in severe cases, death. Current therapeutic standards for neonates include hypothermia, which offers partial efficacy. Currently, there are no pharmacological interventions available to alleviate HIE, promoting the need for further research. Glucagon-like-peptide-1 receptor (GLP-1R) agonists have become a potential therapeutic target due to their anti-inflammatory and neuroprotective role in various insults to the central nervous system. However, the role of GLP-1R in M1/M2 microglial polarization and regulation in the context of neonatal HIBI is still unclear.Therefore, it is critical to study the mechanism and modulation of microglia through GLP-1R in HIBI. This study aims to investigate the neuroprotective effects of GLP-1R agonists Terzepatide and Semaglutide in neonatal HIBI. We hypothesize that these agonists will promote neuroprotection by shifting microglial polarization towards the M2 anti-inflammatory phenotype, alleviating injury. We will utilize a HIBI model induced in CD1 transgenic and wild-type mice, followed by drug intervention, and measure short- and long-term neurobehavioral function. We will also assess brain morphology through staining and assess M1/M2 microglial polarization through inflammatory markers via western blots, immunohistochemistry, and primers in qPCR. This study will help elucidate the neuroprotective mechanism of GLP-1R agonists, offering new therapeutic interventions for clinical practice.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ali, Muhammad
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~